Professor Godefridus J Peters

All Stories

Nucleo(s)tide metabolism as basis for drug development; the Anne Simmonds award lecture

Article • Nucleosides Nucleotides & Nucleic Acids, August 2024, Taylor & Francis

Professor Godefridus J Peters
Effects of lactate dehydrogenase A and GLUT1 inhibition on human endothelial cell migration in relation to their intracellular nucleotide pool

Article • Nucleosides Nucleotides & Nucleic Acids, July 2024, Taylor & Francis

Professor Godefridus J Peters
Evaluation of the combination of gemcitabine, carboplatin, and lactate dehydrogenase A inhibitor on malignant mesothelioma

Article • Nucleosides Nucleotides & Nucleic Acids, June 2024, Taylor & Francis

Professor Godefridus J Peters
Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry

Article • Nucleosides Nucleotides & Nucleic Acids, May 2024, Taylor & Francis

Professor Godefridus J Peters
Novel mass spectrometry-based assay for thymidylate synthase activity

Article • Nucleosides Nucleotides & Nucleic Acids, April 2024, Taylor & Francis

Professor Godefridus J Peters
Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells

Article • Nucleosides Nucleotides & Nucleic Acids, April 2024, Taylor & Francis

Professor Godefridus J Peters
Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells

Article • Cancer Drug Resistance, April 2024, OAE Publishing

Professor Godefridus J Peters
G-Protein Signaling Modulator 2 as a Potential Biomarker in Colorectal Cancer: Integrative Analysis Using Genetic Profiling and Pan-Cancer Studies

Article • Genes, April 2024, MDPI AG

Professor Godefridus J Peters
Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer

Article • Nucleosides Nucleotides & Nucleic Acids, February 2024, Taylor & Francis

Professor Godefridus J Peters
Looking for the unexpected in purine and pyrimidine metabolism

Article • Nucleosides Nucleotides & Nucleic Acids, October 2023, Taylor & Francis

Professor Godefridus J Peters
The Prognostic Value of ASPHD1 and ZBTB12 in Colorectal Cancer: A Machine Learning-Based Integrated Bioinformatics Approach

Article • Cancers, August 2023, MDPI AG

Professor Godefridus J Peters
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma

Article • Cancer and Metastasis Reviews, July 2023, Springer Science + Business Media

Professor Godefridus J Peters
Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

Article • International Journal of Molecular Sciences, May 2023, MDPI AG

Professor Godefridus J Peters
Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma

Article • International Journal of Molecular Sciences, April 2023, MDPI AG

Professor Godefridus J Peters
The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs: Exploring Potential Mechanisms of Resistance

Article • Current Medicinal Chemistry, April 2023, Bentham Science Publishers

Marika Frańczak, Professor Godefridus J Peters
Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • March 2023, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library

Article • European Journal of Pharmacology, January 2023, Elsevier

Professor Godefridus J Peters
Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Article • Cancer Drug Resistance, January 2023, OAE Publishing

Professor Godefridus J Peters
Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Article • Cancer Drug Resistance, January 2023, OAE Publishing

Professor Godefridus J Peters
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth

Article • eLife, December 2022, eLife

Professor Godefridus J Peters
Proceedings of the 19th International Symposium on purine and pyrimidine metabolism in man

Article • Nucleosides Nucleotides & Nucleic Acids, December 2022, Taylor & Francis

Professor Godefridus J Peters
Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo

Article • Journal of Cancer Research and Clinical Oncology, December 2022, Springer Science + Business Media

Professor Godefridus J Peters
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers

Article • Seminars in Cancer Biology, November 2022, Elsevier

Professor Godefridus J Peters
A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships

Article • European Journal of Medicinal Chemistry, September 2022, Elsevier

Manikanta Murahari, Professor Godefridus J Peters
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment

Article • Seminars in Cancer Biology, July 2022, Elsevier

Professor Godefridus J Peters
Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma

Article • Expert Review of Clinical Pharmacology, March 2022, Taylor & Francis

Professor Godefridus J Peters
Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Article • Clinical Cancer Research, February 2022, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells

Article • Nucleosides Nucleotides & Nucleic Acids, February 2022, Taylor & Francis

Professor Godefridus J Peters
Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy

Article • Expert Opinion on Drug Metabolism & Toxicology, January 2022, Taylor & Francis

Professor Godefridus J Peters
A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells

Article • Molecules, December 2021, MDPI AG

Professor Godefridus J Peters
Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters

Article • Cancers, November 2021, MDPI AG

Professor Godefridus J Peters
New insights in research on purine and pyrimidine metabolism

Article • Nucleosides Nucleotides & Nucleic Acids, October 2021, Taylor & Francis

Professor Godefridus J Peters
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

Article • Critical Reviews in Oncology/Hematology, October 2021, Elsevier

Professor Godefridus J Peters
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

Article • Drug Resistance Updates, September 2021, Elsevier

Professor Godefridus J Peters
Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)

Article • Cancers, August 2021, MDPI AG

Professor Godefridus J Peters
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems

Article • Expert Opinion on Drug Metabolism & Toxicology, June 2021, Taylor & Francis

Professor Godefridus J Peters
Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma

Article • Epigenetics, May 2021, Taylor & Francis

Professor Godefridus J Peters
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Article • Journal of Cancer Research and Clinical Oncology, April 2021, Springer Science + Business Media

Professor Godefridus J Peters
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer

Article • Critical Reviews in Oncology/Hematology, April 2021, Elsevier

Professor Godefridus J Peters
Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma

Article • Frontiers in Oncology, March 2021, Frontiers

Manikanta Murahari, Professor Godefridus J Peters
Disrupters of the Thymidylate Synthase Homodimer Accelerate Its Proteasomal Degradation and Inhibit Cancer Growth.

Article • March 2021, American Chemical Society (ACS)

Professor Godefridus J Peters
Disrupters of the Thymidylate Synthase Homodimer Accelerate Its Proteasomal Degradation and Inhibit Cancer Growth.

Article • March 2021, American Chemical Society (ACS)

Professor Godefridus J Peters
Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

Article • January 2021, OAE Publishing

Professor Godefridus J Peters
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Article • January 2021, OAE Publishing

Professor Godefridus J Peters
The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy

Article • Cancer Treatment and Research Communications, January 2021, Elsevier

Professor Godefridus J Peters
The role of the microbiome in drug resistance in gastrointestinal cancers

Article • Expert Review of Anticancer Therapy, December 2020, Taylor & Francis

Professor Godefridus J Peters
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

Article • Cancers, November 2020, MDPI AG

Professor Godefridus J Peters
“Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer

Article • Cancers, October 2020, MDPI AG

Daniel Liu, Professor Godefridus J Peters
11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy

Article • Journal of Nuclear Medicine, October 2020, Society of Nuclear Medicine

Professor Godefridus J Peters
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

Article • Frontiers in Cell and Developmental Biology, October 2020, Frontiers

Professor Godefridus J Peters
The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer

Article • Anticancer Research, September 2020, International Institute of Anticancer Research

Professor Godefridus J Peters
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Article • Experimental Hematology and Oncology, August 2020, Springer Science + Business Media

Professor Godefridus J Peters
Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase

Article • Nucleosides Nucleotides & Nucleic Acids, July 2020, Taylor & Francis

Professor Godefridus J Peters
Resistance to differentiation affects ribo- and deoxyribonucleotide pools and sensitivity to pyrimidine metabolism antagonists in HL60 cells

Article • Nucleosides Nucleotides & Nucleic Acids, July 2020, Taylor & Francis

Professor Godefridus J Peters
Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis

Article • British Journal of Cancer, July 2020, Springer Science + Business Media

Professor Godefridus J Peters
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds

Article • British Journal of Cancer, June 2020, Springer Science + Business Media

Professor Godefridus J Peters
NUC-1031 in biliary tract cancer: from bench to bedside and back?

Article • Cancer Chemotherapy and Pharmacology, May 2020, Springer Science + Business Media

Professor Godefridus J Peters
The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment

Article • Expert Opinion on Investigational Drugs, May 2020, Taylor & Francis

Professor Godefridus J Peters
Targeting telomerase for its advent in cancer therapeutics

Article • Medicinal Research Reviews, May 2020, Wiley

Professor Godefridus J Peters
Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia

Article • Nucleosides Nucleotides & Nucleic Acids, April 2020, Taylor & Francis

Professor Godefridus J Peters
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?

Article • Expert Opinion on Pharmacotherapy, April 2020, Taylor & Francis

Professor Godefridus J Peters
RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier

Article • International Journal of Molecular Sciences, April 2020, MDPI AG

Professor Godefridus J Peters
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study

Article • Cancer Chemotherapy and Pharmacology, April 2020, Springer Science + Business Media

Professor Godefridus J Peters
Recent updates on purine and pyrimidine metabolism in physiological and pathological settings

Article • Nucleosides Nucleotides & Nucleic Acids, March 2020, Taylor & Francis

Professor Godefridus J Peters
The continuous rediscovery and the benefit–risk ratio of thioguanine, a comprehensive review

Article • Expert Opinion on Drug Metabolism & Toxicology, February 2020, Taylor & Francis

Professor Godefridus J Peters
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies

Article • Seminars in Cancer Biology, February 2020, Elsevier

Professor Godefridus J Peters
Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Article • Journal of Cellular Physiology, January 2020, Wiley

Daniel Liu, Professor Godefridus J Peters
3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma

Article • Molecules, January 2020, MDPI AG

Professor Godefridus J Peters
CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage

Article • Molecules, December 2019, MDPI AG

Professor Godefridus J Peters
Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance

Article • Current Medicinal Chemistry, December 2019, Bentham Science Publishers

Professor Godefridus J Peters
Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?

Article • JCO Precision Oncology, December 2019, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment

Article • Current Pharmaceutical Design, November 2019, Bentham Science Publishers

Professor Godefridus J Peters
Thiopurines with low-dose allopurinol (ThiLDA)—a prospective clinical one-way crossover trial

Article • European Journal of Clinical Pharmacology, October 2019, Springer Science + Business Media

Professor Godefridus J Peters
Breastfeeding during R-CHOP chemotherapy: please abstain!

Article • European Journal of Cancer, September 2019, Elsevier

Professor Godefridus J Peters
Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

Article • Biochemical Pharmacology, August 2019, Elsevier

Professor Godefridus J Peters
Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines

Article • International Journal of Molecular Sciences, July 2019, MDPI AG

Professor Godefridus J Peters
Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells

Article • Anticancer Research, July 2019, International Institute of Anticancer Research

Professor Godefridus J Peters
From ‘Targeted Therapy’ to Targeted Therapy

Article • Anticancer Research, July 2019, International Institute of Anticancer Research

Professor Godefridus J Peters
To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology

Article • Anticancer Research, July 2019, International Institute of Anticancer Research

Professor Godefridus J Peters
Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer

Article • Anticancer Research, July 2019, International Institute of Anticancer Research

Professor Godefridus J Peters
Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

Article • Expert Review of Anticancer Therapy, May 2019, Taylor & Francis

Professor Godefridus J Peters, Robin van den Borg
Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells

Article • Cancers, May 2019, MDPI AG

Professor Luciano Saso, Professor Godefridus J Peters
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

Article • British Journal of Clinical Pharmacology, April 2019, Wiley

Professor Godefridus J Peters
E-drug delivery: a futuristic approach

Article • Drug Discovery Today, April 2019, Elsevier

Khushwant Yadav, Professor Godefridus J Peters
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation

Article • Leukemia Research, April 2019, Elsevier

Professor Godefridus J Peters
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment

Article • Expert Opinion on Investigational Drugs, March 2019, Taylor & Francis

Elisa Giovannetti, Professor Godefridus J Peters
Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases

Article • Journal of Experimental & Clinical Cancer Research, March 2019, Springer Science + Business Media

Professor Godefridus J Peters
DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.

Article • Nucleosides Nucleotides & Nucleic Acids, January 2019, Taylor & Francis

Professor Godefridus J Peters
Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor

Article • Nucleosides Nucleotides & Nucleic Acids, January 2019, Taylor & Francis

Professor Godefridus J Peters
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Article • EBioMedicine, January 2019, Elsevier

Professor Godefridus J Peters
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study

Article • British Journal of Cancer, November 2018, Springer Science + Business Media

Professor Godefridus J Peters
WDR48 (WD repeat domain 48)

Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, October 2018, INIST-CNRS

Professor Godefridus J Peters
Subcellular localization of several structurally different tyrosine kinase inhibitors

Article • ADMET & DMPK, September 2018, International Association of Physical Chemists (IAPC)

Professor Godefridus J Peters
Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited

Article • Expert Review of Precision Medicine and Drug Development, September 2018, Taylor & Francis

Professor Godefridus J Peters, Renske Hebing
Abstract 5861: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1

Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma

Article • Pharmacogenomics, June 2018, Future Medicine

Professor Godefridus J Peters
Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies

Article • Computational Biology and Chemistry, June 2018, Elsevier

Professor Godefridus J Peters
Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.

Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.

Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients

Article • Nucleosides Nucleotides & Nucleic Acids, May 2018, Taylor & Francis

Professor Godefridus J Peters
Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines

Article • Nucleosides Nucleotides & Nucleic Acids, May 2018, Taylor & Francis

Professor Godefridus J Peters
Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks

Article • European Respiratory Journal, May 2018, European Respiratory Society (ERS)

Professor Godefridus J Peters
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

Article • Oncotarget, February 2018, Impact Journals, LLC

Professor Godefridus J Peters
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide

Article • Investigational New Drugs, February 2018, Springer Science + Business Media

Professor Godefridus J Peters
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

Article • Cancer Drug Resistance, January 2018, OAE Publishing

Professor Godefridus J Peters
Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group

Article • Cancer Chemotherapy and Pharmacology, December 2017, Springer Science + Business Media

Dr. Paola Perego, Professor Godefridus J Peters
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools

Article • Annals of Oncology, November 2017, Elsevier

Professor Godefridus J Peters
Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies

Article • European Journal of Medicinal Chemistry, October 2017, Elsevier

Manikanta Murahari, Professor Godefridus J Peters
The potential of multi-compound nanoparticles to bypass drug resistance in cancer

Article • Cancer Chemotherapy and Pharmacology, September 2017, Springer Science + Business Media

Professor Godefridus J Peters
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

Article • OncoTargets and Therapy, September 2017, Dove Medical Press

Professor Godefridus J Peters
Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer

Article • Expert Opinion on Drug Metabolism & Toxicology, July 2017, Taylor & Francis

Professor Joseph Sweeney, Professor Godefridus J Peters
Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative

Article • British Journal of Cancer, June 2017, Springer Science + Business Media

Professor Godefridus J Peters
Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate

Article • Pharmacogenomics, June 2017, Future Medicine

Professor Godefridus J Peters
Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring

Article • Therapeutic Drug Monitoring, June 2017, Wolters Kluwer Health

Professor Godefridus J Peters
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN

Article • Oncotarget, May 2017, Impact Journals, LLC

Professor Godefridus J Peters
A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.

Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Loont investeren in preventie?

Article • Tijdschrift voor bedrijfs- en verzekeringsgeneeskunde, May 2017, Springer Science + Business Media

Professor Godefridus J Peters
Erratum to: Glutamate and α-ketoglutarate: key players in glioma metabolism

Article • Amino Acids, April 2017, Springer Science + Business Media

Professor Godefridus J Peters
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures

Article • BMC Cancer, March 2017, Springer Science + Business Media

Professor Godefridus J Peters
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer

Article • Drug Resistance Updates, March 2017, Elsevier

Professor Godefridus J Peters
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

Article • Journal of Hematology & Oncology, January 2017, Springer Science + Business Media

Professor Godefridus J Peters
Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer

Article • ADMET & DMPK, December 2016, International Association of Physical Chemists (IAPC)

Professor Godefridus J Peters
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1

Article • Nucleosides Nucleotides & Nucleic Acids, December 2016, Taylor & Francis

Professor Godefridus J Peters
The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines

Article • Nucleosides Nucleotides & Nucleic Acids, December 2016, Taylor & Francis

Professor Godefridus J Peters
Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA

Article • Nucleosides Nucleotides & Nucleic Acids, December 2016, Taylor & Francis

Professor Godefridus J Peters
Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil

Article • Nucleosides Nucleotides & Nucleic Acids, December 2016, Taylor & Francis

Professor Godefridus J Peters
Advances in purine and pyrimidine metabolism in health and diseases

Article • Nucleosides Nucleotides & Nucleic Acids, December 2016, Taylor & Francis

Professor Godefridus J Peters
hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

Article • The Oncologist, November 2016, Oxford University Press (OUP)

Professor Godefridus J Peters
Glutamate and α-ketoglutarate: key players in glioma metabolism

Article • Amino Acids, October 2016, Springer Science + Business Media

Professor Godefridus J Peters
New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Article • OncoTargets and Therapy, October 2016, Dove Medical Press

Professor Godefridus J Peters, Elisa Giovannetti
ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors

Article • ADMET & DMPK, October 2016, International Association of Physical Chemists (IAPC)

Professor Godefridus J Peters
P2.09: cMET in NSCLC: Expression, Amplification and Mutations

Article • Journal of Thoracic Oncology, October 2016, Elsevier

Professor Godefridus J Peters
Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

Article • Frontiers in Pharmacology, September 2016, Frontiers

Lonneke Timmers, Professor Godefridus J Peters
Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

Article • Journal of Experimental & Clinical Cancer Research, September 2016, Springer Science + Business Media

Professor Godefridus J Peters
cMET Exon 14 Skipping: From the Structure to the Clinic

Article • Journal of Thoracic Oncology, September 2016, Elsevier

Professor Godefridus J Peters
Abstract 4725: Inhibition of DNA methyltransferase by RX-3117 (fluorocyclopentenylcytosine) leads to upregulation of hypomethylated targets

Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 4336: Spliceosome inhibition as a novel therapeutic option in acute leukemia

Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 332: Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma

Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 2242: cMET in non-small cell lung cancer: pieces of the puzzle

Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Letter

Article • Clinical Cancer Research, May 2016, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia

Article • Haematologica, April 2016, Ferrata Storti Foundation (Haematologica)

Professor Godefridus J Peters
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective

Article • Cancer Chemotherapy and Pharmacology, March 2016, Springer Science + Business Media

Professor Godefridus J Peters
On the pharmacogenetics of non-small cell lung cancer treatment

Article • Expert Opinion on Drug Metabolism & Toxicology, February 2016, Taylor & Francis

Professor Godefridus J Peters
Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open

Article • Journal of Clinical Oncology, February 2016, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Erratum

Article • Autophagy, February 2016, Taylor & Francis

Dr Janos KristonVizi, Juan Segura-Aguilar, Professor Nektarios Tavernarakis, Dr Reinhard Dechant, Dr Vasilis J Promponas, Professor Marc Lecuit, Professor Paula I. Moreira, Professor Mark Cragg, Executive Director, The Hormel Institute Robert Clarke, Dr Eleonora García Véscovi, Professor Jean-François Beaulieu, Shile Huang, Maria João Sousa, Professor Godefridus J Peters, PD Dipl.-Ing. Dr. techn. Werner J Kovacs
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Article • Expert Review of Anticancer Therapy, January 2016, Taylor & Francis

Professor Godefridus J Peters
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Article • Autophagy, January 2016, Taylor & Francis

Professor CIRO ISIDORO, Dr Akira Matsuura, Prof Hirokazu Arimoto, Professor Marc Diederich, Maria Vaccaro, Professor Abdel Halim Harrath, Professor Hyun Kyu Song, Dr Takeshi Noda, Dr Regina Menezes, Dr Janos KristonVizi, Cristina Muñoz-Pinedo, Professor Nektarios Tavernarakis, Juan Segura-Aguilar, Professor Marc Lecuit, Leonardo Travassos, Prof Robert Bryson-Richardson, Isabelle Dugail, PD Dipl.-Ing. Dr. techn. Werner J Kovacs, Dr Luca Galluzzi, Dr Reinhard Dechant, Dr. Sandra Moreno, Maurizio Molinari, Dr Vasilis J Promponas, Professor Günther Weindl, Dr Marc Etienne Poirot, Professor Paula I. Moreira, Maria João Sousa, Dr Janna Morrison, Professor Mark Cragg, Executive Director, The Hormel Institute Robert Clarke, Dr Eleonora García Véscovi, Paula Ludovico, Professor Jean-François Beaulieu, Shile Huang, Professor George Perry, Professor Godefridus J Peters
Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review

Article • World Journal of Gastroenterology, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

Professor Godefridus J Peters
Role of Akt signaling in resistance to DNA-targeted therapy

Article • World Journal of Clinical Oncology, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

Professor Godefridus J Peters
The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis

Article • January 2016, Springer Science + Business Media

Professor Godefridus J Peters
Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma

Article • Seminars in Cancer Biology, December 2015, Elsevier

Professor Godefridus J Peters
Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance

Article • International Journal of Cancer, November 2015, Wiley

Professor Godefridus J Peters
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Article • Oncotarget, October 2015, Impact Journals, LLC

Sarah Kammerer, Professor Godefridus J Peters
Abstract 2622: Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker

Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 1624: Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 4335: Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed

Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia

Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

Article • Journal of Hematology & Oncology, May 2015, Springer Science + Business Media

Professor Godefridus J Peters
A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.

Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Drug transport and metabolism of novel anticancer drugs

Article • Expert Opinion on Drug Metabolism & Toxicology, May 2015, Informa Healthcare

Professor Godefridus J Peters
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Article • Oncotarget, April 2015, Impact Journals, LLC

Professor Godefridus J Peters
Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors

Article • ADMET & DMPK, March 2015, International Association of Physical Chemists (IAPC)

Professor Godefridus J Peters
Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future

Article • The Oncologist, March 2015, Oxford University Press (OUP)

Professor Godefridus J Peters
Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine

Article • The International Journal of Biochemistry & Cell Biology, March 2015, Elsevier

Professor Godefridus J Peters
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Article • Cellular Oncology, February 2015, Springer Science + Business Media

Professor Godefridus J Peters
Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters

Article • Expert Opinion on Drug Metabolism & Toxicology, January 2015, Informa Healthcare

Professor Godefridus J Peters
MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer

Article • Current Pharmacology Reports, January 2015, Springer Science + Business Media

Professor Godefridus J Peters
Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer

Article • Pteridines, January 2015, De Gruyter

Professor Godefridus J Peters
Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib

Article • Current Drug Targets, December 2014, Bentham Science Publishers

Professor Godefridus J Peters
The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib

Article • Current Drug Targets, December 2014, Bentham Science Publishers

Professor Godefridus J Peters
Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

Article • SpringerPlus, December 2014, Springer Science + Business Media

Professor Godefridus J Peters
EZH2 (enhancer of zeste homolog 2 (Drosophila))

Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2014, INIST-CNRS

Professor Godefridus J Peters
Calcium/Magnesium Infusion for Oxaliplatin-Induced Neuropathy: Protective or Not?

Article • Journal of Clinical Oncology, October 2014, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
On the use of pharmacogenetics in cancer treatment and clinical trials

Article • European Journal of Cancer, October 2014, Elsevier

Dr Jacques Robert, Professor Godefridus J Peters
Abstract 2989: High-dose, intermittent sunitinib as an alternative treatment strategy

Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients

Article • PLoS ONE, September 2014, PLOS

Professor Godefridus J Peters
Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”?

Article • Current Pharmaceutical Design, June 2014, Bentham Science Publishers

Professor Godefridus J Peters
Design and Synthesis of Quinazolinone Tagged Acridones as Cytotoxic Agents and Their Effects on EGFR Tyrosine Kinase

Article • Archiv der Pharmazie, May 2014, Wiley

Professor Godefridus J Peters
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

Article • Cancer Chemotherapy and Pharmacology, April 2014, Springer Science + Business Media

Professor Godefridus J Peters
miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters
Radiosensitization by Thymidine Phosphorylase Inhibitor in Thymidine Phosphorylase Negative and Overexpressing Bladder Cancer Cell Lines

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters
Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters, joseph ciccolini
Novel Developments in the Use of Antimetabolites

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters
Proceedings of the 15th International Symposium on Purine and Pyrimidine Metabolism in Man

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters
Novel Developments in Metabolic Disorders of Purine and Pyrimidine Metabolism and Therapeutic Applications of Their Analogs

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters
Assessment of Mercaptopurine (6MP) Metabolites and 6MP Metabolic Key-Enzymes in Childhood Acute Lymphoblastic Leukemia

Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

Professor Godefridus J Peters
USP1 (ubiquitin specific peptidase 1)

Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, April 2014, INIST-CNRS

Professor Godefridus J Peters
A Polymorphism in the promoter is Associated with EZH2 Expression but not with Outcome in Advanced Pancreatic Cancer Patients

Article • Pharmacogenomics, April 2014, Taylor & Francis

Professor Godefridus J Peters
Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1)

Article • Cancer Chemotherapy and Pharmacology, March 2014, Springer Science + Business Media

Professor Godefridus J Peters
MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside

Article • Current Medicinal Chemistry, February 2014, Bentham Science Publishers

Elisa Giovannetti, Professor Godefridus J Peters
Positioning of aminopeptidase inhibitors in next generation cancer therapy

Article • Amino Acids, January 2014, Springer Science + Business Media

Professor Godefridus J Peters
Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation

Article • JNCI Journal of the National Cancer Institute, December 2013, Oxford University Press (OUP)

Professor Godefridus J Peters
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

Article • Cancer Research, November 2013, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
MIR211 (microRNA 211)

Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2013, INIST-CNRS

Professor Godefridus J Peters
The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study

Article • Journal of Crohn s and Colitis, November 2013, Oxford University Press (OUP)

Dr Ad A van Bodegraven, Professor Godefridus J Peters
Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system.

Article • Molecular Cancer Therapeutics, November 2013, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia

Article • British Journal of Cancer, October 2013, Nature

Dr Filippo Minutolo, Professor Godefridus J Peters
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)

Article • Investigational New Drugs, September 2013, Springer Science + Business Media

Professor Godefridus J Peters
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma

Article • Oncology Letters, September 2013, Spandidos Publications

Professor Godefridus J Peters
USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy

Article • Molecular Cancer, August 2013, Springer Science + Business Media

Professor Godefridus J Peters
“One Marker Does Not Fit All”: Additional Translational and Validation Studies Are Needed to Identify Faithful Predictors of Pemetrexed Activity in Mesothelioma

Article • Journal of Thoracic Oncology, August 2013, Elsevier

Professor Godefridus J Peters
Gender, Cytidine Deaminase, and 5-Aza/Decitabine—Letter

Article • Clinical Cancer Research, May 2013, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[18F]fluorothymidine Positron Emission Tomography

Article • PLoS ONE, May 2013, PLOS

Professor Godefridus J Peters
Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression

Article • Pteridines, May 2013, De Gruyter

Professor Godefridus J Peters
Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI

Article • Pteridines, May 2013, De Gruyter

Professor Godefridus J Peters
Thymidylate synthase inhibitors for thoracic tumors

Article • Pteridines, May 2013, De Gruyter

Professor Godefridus J Peters
Folates and antifolates in rheumatoid arthritis

Article • Pteridines, May 2013, De Gruyter

Professor Godefridus J Peters
DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

Article • PLoS ONE, April 2013, PLOS

Dr Boudewijn J Braakhuis, Professor Godefridus J Peters
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family

Article • Cell Death and Differentiation, April 2013, Springer Science + Business Media

Professor Godefridus J Peters
Abstract 4628: Alterations in FPGS splicing as a plausible underlying mechanism of MTX resistance in ALL.

Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer:XPD-Lys751Glnpolymorphism strikes back

Article • International Journal of Cancer, March 2013, Wiley

Dr Michele Milella, Professor Godefridus J Peters
MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1

Article • APOPTOSIS, March 2013, Springer Science + Business Media

Professor Godefridus J Peters
Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?

Article • Critical Reviews in Oncology/Hematology, March 2013, Elsevier

Professor Godefridus J Peters
Chemosensitizing acridones: In vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies

Article • Journal of Molecular Graphics and Modelling, March 2013, Elsevier

Professor Godefridus J Peters
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms

Article • Annals of Oncology, March 2013, Elsevier

Professor Godefridus J Peters
Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure

Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)

Article • Current Pharmaceutical Design, February 2013, Bentham Science Publishers

Professor Godefridus J Peters
Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

Article • Current Pharmaceutical Design, February 2013, Bentham Science Publishers

Professor Godefridus J Peters
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer

Article • Current Pharmaceutical Design, February 2013, Bentham Science Publishers

Professor Godefridus J Peters
Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

Article • Current Pharmaceutical Design, February 2013, Bentham Science Publishers

Professor Godefridus J Peters
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

Article • Experimental Hematology and Oncology, January 2013, Springer Science + Business Media

Professor Godefridus J Peters
Cancer therapeutics and research: novel developments

Article • journal of cancer therapeutics and research, January 2013, Herbert Publications PVT LTD

Professor Godefridus J Peters
Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer

Article • Neoplasia, January 2013, Elsevier

Professor Godefridus J Peters
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer

Article • Critical Reviews in Oncogenesis, January 2013, Begell House

Professor Godefridus J Peters
Role of E3 ubiquitin ligases in lung cancer

Article • World Journal of Clinical Oncology, January 2013, Baishideng Publishing Group Co., Limited (formerly WJG Press)

Professor Godefridus J Peters
EO9 (Apaziquone): from the clinic to the laboratory and back again

Article • British Journal of Pharmacology, December 2012, Wiley

Professor Godefridus J Peters
TAS-102: more than an antimetabolite

Article • The Lancet Oncology, December 2012, Elsevier

Professor Godefridus J Peters
High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer

Article • PLoS ONE, November 2012, PLOS

Professor Godefridus J Peters
441 Quality Assurance of Biomarker Assays in Clinical Trials

Article • European Journal of Cancer, November 2012, Elsevier

Professor Godefridus J Peters
The use of capecitabine in daily practice: a study on adherence and patients&#39; experiences

Article • Patient Preference and Adherence, October 2012, Taylor & Francis

Lonneke Timmers, Professor Godefridus J Peters
Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib

Article • Current Topics in Medicinal Chemistry, October 2012, Bentham Science Publishers

Professor Godefridus J Peters
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Article • Lung Cancer, October 2012, Elsevier

Professor Godefridus J Peters
Research Highlights: Highlights from the Latest Articles in Pharmacogenomics of Irinotecan/Cisplatin Toxicity

Article • Pharmacogenomics, October 2012, Taylor & Francis

Professor Godefridus J Peters
EGF Receptor-Targeted Therapy in Non-Small-Cell Lung Cancer: Role of Germline Polymorphisms in Outcome and Toxicity

Article • Future Oncology, August 2012, Taylor & Francis

Professor Godefridus J Peters
Pharmacogenetics of Conventional Chemotherapy in Non-Small-Cell Lung Cancer: A Changing Landscape?

Article • Pharmacogenomics, July 2012, Taylor & Francis

Professor Godefridus J Peters
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations

Article • Current Pharmaceutical Design, May 2012, Bentham Science Publishers

Professor Godefridus J Peters
Guidelines for the use and interpretation of assays for monitoring autophagy

Article • Autophagy, April 2012, Taylor & Francis

Dave Bridges, Professor CIRO ISIDORO, Professor George Perry, Dr Takeshi Noda, Professor Nektarios Tavernarakis, Matthias Gaestel, Dr Francesca Demarchi, Maria Vaccaro, Juan Segura-Aguilar, Leonardo Travassos, Manoj B Menon, Isabelle Dugail, Dr Legembre Patrick, Dr Marc Etienne Poirot, Professor Paula I. Moreira, Executive Director, The Hormel Institute Robert Clarke, Professor Godefridus J Peters
Abstract 186: High-throughput microRNA (miRNAs) arrays unravel the prognostic role of miR211 in pancreatic cancer

Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 1770: Metabolism and mechanism of action of fluorocyclopentenylcytosine (RX-3117)

Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine

Article • Expert Opinion on Investigational Drugs, March 2012, Informa Healthcare

Professor Godefridus J Peters
TFAP2E-DKK4and Chemoresistance in Colorectal Cancer

Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2012, New England Journal of Medicine (NEJM/MMS)

Professor Godefridus J Peters
EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group

Article • European Journal of Cancer Supplements, March 2012, Elsevier

Professor Godefridus J Peters
“The only thing I know is that I know nothing”: 5-fluorouracil in human milk

Article • Annals of Oncology, February 2012, Elsevier

Professor Godefridus J Peters
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice

Article • Critical Reviews in Oncology/Hematology, February 2012, Elsevier

Professor Godefridus J Peters
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients wi...

Article • Journal of Pharmacology and Experimental Therapeutics, January 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

Professor Godefridus J Peters
Effect of staurosporine and ucn-01 on gemcitabine cytotoxicity in relation to cell cycle effects and p53 status

Article • journal of cancer therapeutics and research, January 2012, Herbert Publications PVT LTD

Professor Godefridus J Peters
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer

Article • Biochemical Pharmacology, January 2012, Elsevier

Professor Godefridus J Peters
Allopurinol Enhances the Activity of Hypoxanthine-Guanine Phosphoribosyltransferase in Inflammatory Bowel Disease Patients During Low-Dose Thiopurine Therapy: Preliminary Data of an Ongoing Series

Article • Nucleosides Nucleotides & Nucleic Acids, December 2011, Taylor & Francis

Dr Ad A van Bodegraven, Professor Godefridus J Peters
DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens

Article • Current Drug Metabolism, December 2011, Bentham Science Publishers

Professor Godefridus J Peters
The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment

Article • Current Drug Metabolism, December 2011, Bentham Science Publishers

Professor Godefridus J Peters
Deoxyribose Protects Against Rapamycin-Induced Cytotoxicity in Colorectal Cancer Cells In Vitro

Article • Nucleosides Nucleotides & Nucleic Acids, December 2011, Taylor & Francis

Professor Godefridus J Peters
Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LCMSMS

Article • Nucleosides Nucleotides & Nucleic Acids, December 2011, Taylor & Francis

Professor Godefridus J Peters
Gout and Hyperuricemia in Japan: Perspectives for International Research on Purines and Pyrimidines in Man

Article • Nucleosides Nucleotides & Nucleic Acids, December 2011, Taylor & Francis

Professor Godefridus J Peters
Lipophilic Prodrugs and Formulations of Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer

Article • Nucleosides Nucleotides & Nucleic Acids, December 2011, Taylor & Francis

Professor Godefridus J Peters
Association Between DNA-repair Polymorphisms and Survival in Pancreatic Cancer Patients Treated with Combination Chemotherapy

Article • Pharmacogenomics, November 2011, Taylor & Francis

Professor Godefridus J Peters
TYMP (thymidine phosphorylase)

Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2011, INIST-CNRS

Professor Godefridus J Peters
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation

Article • European Journal of Medicinal Chemistry, November 2011, Elsevier

Dr Filippo Minutolo, Dr Laura Betti, Dr Laura Betti, Professor Godefridus J Peters
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

Article • Investigational New Drugs, October 2011, Springer Science + Business Media

Professor Godefridus J Peters
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

Article • British Journal of Cancer, October 2011, Springer Science + Business Media

Professor Godefridus J Peters
Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies

Article • European Journal of Pharmaceutical Sciences, July 2011, Elsevier

Professor Godefridus J Peters
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients

Article • Annals of Oncology, June 2011, Oxford University Press (OUP)

Dr Federico Cappuzzo, Professor Godefridus J Peters
Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer

Article • Biopreservation and Biobanking, June 2011, Mary Ann Liebert Inc

Professor Godefridus J Peters
Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine

Article • British Journal of Pharmacology, May 2011, Wiley

Professor Godefridus J Peters, Dr Ad A van Bodegraven
Tolerability and Safety of Conventional Thiopurines Concomitantly With Allopurinol in IBD-Patients With a Skewed Thiopurine Metabolism

Article • Gastroenterology, May 2011, Elsevier

Professor Godefridus J Peters
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 746: Acquired bortezomib resistance in non-small cell lung cancer is associated with overexpression of the mutated β5 proteasome subunit

Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 2852: Lysosomal sequestration of sunitinib may play a role in its resistance

Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 1941: TRAIL-induced kinase activation in Non small cell lung cancer cells

Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Discovery of N -Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells

Article • Journal of Medicinal Chemistry, March 2011, American Chemical Society (ACS)

Dr Filippo Minutolo, Dr Laura Betti, Dr Laura Betti, Professor Godefridus J Peters
Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors

Article • British Journal of Cancer, March 2011, Springer Science + Business Media

Professor Godefridus J Peters
Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients

Article • Journal of Thoracic Oncology, February 2011, Elsevier

Dr Federico Cappuzzo, Professor Godefridus J Peters
Impact of ABCG2 Polymorphisms on the Clinical Outcome and Toxicity of Gefitinib in Non-Small-Cell Lung Cancer Patients

Article • Pharmacogenomics, February 2011, Taylor & Francis

Professor Godefridus J Peters
Analysis of Drug Interactions

Article • January 2011, Springer Science + Business Media

Professor Godefridus J Peters
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer

Article • Frontiers in Bioscience, January 2011, IMR Press

Professor Godefridus J Peters
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Article • World Journal of Clinical Oncology, January 2011, Baishideng Publishing Group Co., Limited (formerly WJG Press)

Professor Godefridus J Peters
46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?

Article • Cancer Treatment Reviews, November 2010, Elsevier

Professor Godefridus J Peters
189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

Article • European Journal of Cancer Supplements, November 2010, Elsevier

Professor Godefridus J Peters
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

Article • July 2010, Wolters Kluwer Health

Professor Godefridus J Peters
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin

Article • Medical Oncology, June 2010, Springer Science + Business Media

Professor Godefridus J Peters
Limited Intra-Individual Variability in Hypoxanthine-Guanine Phosphoribosyl Transferase, Thiopurine S-Methyl Transferase, and Xanthine Oxidase Activity in Inflammatory Bowel Disease Patients During 6-Thioguanine Therapy

Article • Nucleosides Nucleotides & Nucleic Acids, June 2010, Taylor & Francis

Dr Ad A van Bodegraven, Professor Godefridus J Peters
Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells

Article • Nucleosides Nucleotides & Nucleic Acids, June 2010, Taylor & Francis

Dr Filippo Minutolo, Professor Godefridus J Peters
Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells

Article • Nucleosides Nucleotides & Nucleic Acids, June 2010, Taylor & Francis

Professor Godefridus J Peters
Purine and Pyrimidine Metabolism in the Fist Decade of the 21st Century—Highlights and Perspectives

Article • Nucleosides Nucleotides & Nucleic Acids, June 2010, Taylor & Francis

Professor Godefridus J Peters
The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues

Article • Nucleosides Nucleotides & Nucleic Acids, June 2010, Taylor & Francis

Professor Godefridus J Peters
MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

Article • Cancer Research, June 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

Article • Clinical Cancer Research, May 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing

Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Abstract 2146: DNA copy number profiles associated with clinical outcome in advanced colorectal cancer patients treated with folfiri and aliri regimens

Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity

Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Abstract 1261: TRAIL-induced pro- and antiapoptotic kinase activation in non-small cell lung cancer cells

Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2

Article • Molecular Cancer Therapeutics, April 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Association of Polymorphisms inAKT1andEGFRwith Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib

Article • Molecular Cancer Therapeutics, March 2010, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines

Article • Cancer Science, February 2010, Wiley

Professor Godefridus J Peters
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

Article • Investigational New Drugs, January 2010, Springer Science + Business Media

Professor Godefridus J Peters
Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

Article • Current Drug Targets, January 2010, Bentham Science Publishers

Professor Godefridus J Peters
Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

Article • Investigational New Drugs, December 2009, Springer Science + Business Media

Professor Godefridus J Peters
Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer

Article • Current Medicinal Chemistry, December 2009, Bentham Science Publishers

Professor Godefridus J Peters
Abstract B65: Overexpression of MRP4 or MRP5 confers resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

Article • Molecular Cancer Therapeutics, December 2009, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance

Article • Current Drug Metabolism, November 2009, Bentham Science Publishers

Dr Ad A van Bodegraven, Professor Godefridus J Peters
OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib

Article • European Journal of Cancer Supplements, October 2009, Elsevier

Professor Godefridus J Peters
Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents

Article • Journal of Chemotherapy, October 2009, Taylor & Francis

Professor Godefridus J Peters
Polymorphisms in the Enhancer Region of the Thymidylate Synthase Gene Are Associated with Thymidylate Synthase Levels in Normal Tissues but Not in Malignant Tissues of Patients with Colorectal Cancer

Article • Clinical Colorectal Cancer, July 2009, Elsevier

Professor Godefridus J Peters
Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines

Article • Journal of Chemotherapy, June 2009, Taylor & Francis

Professor Godefridus J Peters
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer

Article • Annals of Oncology, June 2009, Elsevier

Professor Godefridus J Peters
Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells

Article • Current Cancer Drug Targets, May 2009, Bentham Science Publishers

Professor Godefridus J Peters
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

Article • Molecular Cancer Therapeutics, May 2009, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center

Article • Molecular Cancer Therapeutics, May 2009, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis

Article • Biochemical Pharmacology, April 2009, Elsevier

Professor Godefridus J Peters
Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins

Article • Molecular Cancer Therapeutics, March 2009, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Intracellular Trafficking of MDR Transporters and Relevance of SNPs

Article • Current Topics in Medicinal Chemistry, February 2009, Bentham Science Publishers

Professor Godefridus J Peters
Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

Article • Scandinavian Journal of Gastroenterology, January 2009, Taylor & Francis

Professor Godefridus J Peters
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

Article • British Journal of Cancer, December 2008, Springer Science + Business Media

Professor Godefridus J Peters
Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent

Article • Cancer Science, October 2008, Wiley

Professor Godefridus J Peters
Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

Article • British Journal of Cancer, August 2008, Springer Science + Business Media

Professor Godefridus J Peters
Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts

Article • Anti-Cancer Drugs, August 2008, Wolters Kluwer Health

Professor Godefridus J Peters
[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study

Article • British Journal of Cancer, July 2008, Springer Science + Business Media

Adriaan Lammertsma, Professor Godefridus J Peters
Functional Inactivity and Mutations of p53 Differentially Affect Sensitivity to 5-Fluorouracil and Antifolate Inhibitors of Thymidylate Synthase (TS) by Altering TS Levels in Colorectal Cancer Cells

Article • Nucleosides Nucleotides & Nucleic Acids, July 2008, Taylor & Francis

Professor Godefridus J Peters
Immunocytochemical Detection of hENT1 and hCNT1 in Normal Tissues, Lung Cancer Cell Lines, and NSCLC Patient Samples

Article • Nucleosides Nucleotides & Nucleic Acids, July 2008, Taylor & Francis

Professor Godefridus J Peters
Selective Protection by Uridine of Growth Inhibition by 5-Fluorouracil (5FU) Mediated by 5FU Incorporation into RNA, But Not the Thymidylate Synthase Mediated Growth Inhibition by 5FU-Leucovorin

Article • Nucleosides Nucleotides & Nucleic Acids, July 2008, Taylor & Francis

Professor Godefridus J Peters
The Role of Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Tumor Behavior

Article • Nucleosides Nucleotides & Nucleic Acids, July 2008, Taylor & Francis

Professor Godefridus J Peters
Trifluorothymidine Induces Cell Death Independently of p53

Article • Nucleosides Nucleotides & Nucleic Acids, July 2008, Taylor & Francis

Professor Godefridus J Peters
Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines

Article • Biochemical Pharmacology, July 2008, Elsevier

Professor Godefridus J Peters
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients

Article • Clinical Cancer Research, March 2008, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo

Article • Cancer Chemotherapy and Pharmacology, February 2008, Springer Science + Business Media

Professor Godefridus J Peters
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

Article • Molecular Pharmacology, January 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

Professor Godefridus J Peters
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia

Article • Leukemia Research, January 2008, Elsevier

Professor Godefridus J Peters
In Vivo and in Vitro Activity And Mechanism Of Action of the Multidrug Cytarabine-L-Glycerylyl-Fluorodeoxyuridine

Article • Nucleosides Nucleotides & Nucleic Acids, November 2007, Taylor & Francis

Professor Godefridus J Peters
Troxacitabine Prodrugs for Pancreatic Cancer

Article • Nucleosides Nucleotides & Nucleic Acids, November 2007, Taylor & Francis

Professor Godefridus J Peters
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines

Article • International Journal of Oncology, October 2007, Spandidos Publications

Dr Anna Tesei, Professor Godefridus J Peters
O 6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor–induced resistance against temozolomide in human melanoma cells

Article • Molecular Cancer Therapeutics, October 2007, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds

Article • Zeitschrift für Ernährungswissenschaft, August 2007, Springer Science + Business Media

Professor Godefridus J Peters
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors

Article • Clinical Cancer Research, June 2007, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies

Article • Cancer Science, June 2007, Wiley

Professor Godefridus J Peters
The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent

Article • Biochemical Pharmacology, May 2007, Elsevier

Professor Godefridus J Peters
Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung

Article • Clinical Cancer Research, April 2007, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
In vivo toxicological effects and spectral studies of organotin(IV) N‐maleoylglycinates M. I. Khan, Musa Kaleem Baloch, Muhammad Ashfaq and G. J. Peters Applied Organometallic Chemistry 2005; 19: 132

Article • Applied Organometallic Chemistry, April 2007, Wiley

Professor Godefridus J Peters
In Vitro Optimization of Non-Small Cell Lung Cancer Activity with Troxacitabine, l-1,3-Dioxolane-cytidine, Prodrugs

Article • Journal of Medicinal Chemistry, April 2007, American Chemical Society (ACS)

Professor Godefridus J Peters
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5‐fluorouracil to patients with colorectal cancer

Article • International Journal of Cancer, April 2007, Wiley

Professor Godefridus J Peters
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

Article • British Journal of Cancer, March 2007, Springer Science + Business Media

Professor Godefridus J Peters
The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry

Article • Journal of Chromatography B, March 2007, Elsevier

Professor Godefridus J Peters
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines

Article • The International Journal of Biochemistry & Cell Biology, January 2007, Elsevier

Professor Godefridus J Peters
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells

Article • British Journal of Cancer, January 2007, Springer Science + Business Media

Professor Godefridus J Peters
Thymidylate synthase inhibitors

Article • Update on Cancer Therapeutics, December 2006, Elsevier

Professor Godefridus J Peters
Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by γ-irradiation

Article • Oncology Reports, October 2006, Spandidos Publications

Professor Godefridus J Peters
Cellular Resistance Against Troxacitabine in Human Cell Lines and Pediatric Patient Acute Myeloid Leukemia Blast Cells

Article • Nucleosides Nucleotides & Nucleic Acids, June 2006, Taylor & Francis

Professor Godefridus J Peters
Enhanced Activity of Deoxycytidine Kinase After Pulsed Low Dose Rate and Single Dose Gamma Irradiation

Article • Nucleosides Nucleotides & Nucleic Acids, June 2006, Taylor & Francis

Professor Godefridus J Peters
Micro-Array Analysis of Resistance for Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunits

Article • Nucleosides Nucleotides & Nucleic Acids, June 2006, Taylor & Francis

Professor Godefridus J Peters
Purine and Pyrimidine Metabolism: a Firm Basis for a Transformed Society

Article • Nucleosides Nucleotides & Nucleic Acids, June 2006, Taylor & Francis

Professor Godefridus J Peters
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines

Article • BMC Cancer, May 2006, Springer Science + Business Media

Professor Godefridus J Peters
Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

Article • Cancer Chemotherapy and Pharmacology, March 2006, Springer Science + Business Media

Professor Godefridus J Peters
Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy

Article • Current Pharmacogenomics, March 2006, Bentham Science Publishers

Professor Godefridus J Peters
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

Article • British Journal of Cancer, December 2005, Springer Science + Business Media

Professor Godefridus J Peters
Expression Microarray Analysis and Oligo Array Comparative Genomic Hybridization of Acquired Gemcitabine Resistance in Mouse Colon Reveals Selection for Chromosomal Aberrations

Article • Cancer Research, November 2005, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
No evidence of gemcitabine accumulation during weekly administration

Article • European Journal of Clinical Pharmacology, November 2005, Springer Science + Business Media

Professor Godefridus J Peters
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant

Article • Cancer Research, October 2005, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Potentiation of in vitro ara‐C cytotoxicity by ribonucleotide reductase inhibitors, cyclin‐dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia

Article • British Journal of Haematology, September 2005, Wiley

Professor Godefridus J Peters
Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures

Article • Investigational New Drugs, September 2005, Springer Science + Business Media

Professor Godefridus J Peters
Pyrimidine and Purine Analogues, Effects on Cell Cycle Regulation and the Role of Cell Cycle Inhibitors to Enhance Their Cytotoxicity

Article • Nucleosides Nucleotides & Nucleic Acids, September 2005, Taylor & Francis

Professor Godefridus J Peters
Erratum for vol. 106, p. 717

Article • Blood, August 2005, American Society of Hematology

Professor Godefridus J Peters
Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia

Article • Blood, July 2005, American Society of Hematology

Professor Godefridus J Peters
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours

Article • Journal of Clinical Pathology, June 2005, BMJ

Professor Godefridus J Peters
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients

Article • Annals of Oncology, June 2005, Oxford University Press (OUP)

Professor Nicol Keith, Professor Godefridus J Peters
Folates and antifolates in the treatment of cancer; role of folic acid supplementation on efficacy of folate and non-folate drugs

Article • Trends in Food Science & Technology, June 2005, Elsevier

Professor Godefridus J Peters
Pharmacokinetics of Bolus 5-Fluorouracil: Relationship Between Dose, Plasma Concentrations, Area-Under-the-Curve and Toxicity

Article • Journal of Chemotherapy, June 2005, Taylor & Francis

Professor Godefridus J Peters
Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

Article • European Journal of Cancer, May 2005, Elsevier

Professor Godefridus J Peters
Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells

Article • Anti-Cancer Drugs, March 2005, Wolters Kluwer Health

Professor Godefridus J Peters
In vivo toxicological effects and spectral studies of organotin(IV)N-maleoylglycinates

Article • Applied Organometallic Chemistry, January 2005, Wiley

Professor Godefridus J Peters
A Non‐Radioactive Sensitive Assay to Measure 5‐Fluorouracil Incorporation into DNA of Solid Tumors

Article • Nucleosides Nucleotides & Nucleic Acids, December 2004, Taylor & Francis

Professor Godefridus J Peters
Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Arabinosylcytosine (ara‐C) in Leukemia and Solid Tumor Cell Lines

Article • Nucleosides Nucleotides & Nucleic Acids, December 2004, Taylor & Francis

Professor Godefridus J Peters
Comparison of mRNA Expression Levels Determined with TAQ–Man and Competitive Template RT–PCR

Article • Nucleosides Nucleotides & Nucleic Acids, December 2004, Taylor & Francis

Professor Godefridus J Peters
Intracellular Thymidylate Synthase Inhibition by Trifluorothymidine in FM3A Cells

Article • Nucleosides Nucleotides & Nucleic Acids, December 2004, Taylor & Francis

Professor Godefridus J Peters
Online Fluorescent Method to Assess BCRP/ABCG2 Activity in Suspension Cells

Article • Nucleosides Nucleotides & Nucleic Acids, December 2004, Taylor & Francis

Professor Godefridus J Peters
Role of Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Fluoropyrimidine Sensitivity and Potential Role of Deoxyribose‐1‐Phosphate

Article • Nucleosides Nucleotides & Nucleic Acids, December 2004, Taylor & Francis

Professor Godefridus J Peters
Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy

Article • Blood, December 2004, American Society of Hematology

Professor Godefridus J Peters
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia

Article • International Journal of Oncology, December 2004, Spandidos Publications

Professor Godefridus J Peters
Prospective Clinical Trials Using a Pharmacogenetic/Pharmacogenomic Approach

Article • Journal of Chemotherapy, November 2004, Taylor & Francis

Professor Godefridus J Peters
Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours

Article • Cancer Chemotherapy and Pharmacology, October 2004, Springer Science + Business Media

Professor Martin O Leach, Professor Godefridus J Peters
Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity

Article • Cancer Letters, September 2004, Elsevier

Professor Godefridus J Peters
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000

Article • Biochemical Pharmacology, August 2004, Elsevier

Dr. José M. Padrón, Professor Godefridus J Peters
Sulfasalazine Down-Regulates the Expression of the Angiogenic Factors Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase and Interleukin-8 in Human Monocytic-Macrophage THP1 and U937 Cells

Article • Molecular Pharmacology, July 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

Professor Godefridus J Peters
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers

Article • Annals of Oncology, July 2004, Elsevier

Professor Godefridus J Peters
The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

Article • Clinical Cancer Research, June 2004, American Association for Cancer Research (AACR)

Professor Godefridus J Peters
Cancer of the esophagus and gastric cardia: recent advances*

Article • Diseases of the Esophagus, June 2004, Oxford University Press (OUP)

Professor Godefridus J Peters
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors

Article • Annals of Oncology, May 2004, Elsevier

Professor Godefridus J Peters
The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase

Article • European Journal of Pharmacology, May 2004, Elsevier

Professor Godefridus J Peters
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

Article • Blood, April 2004, American Society of Hematology

Professor Godefridus J Peters
Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1)

Article • Biochemical Pharmacology, April 2004, Elsevier

Professor Godefridus J Peters
275: Intravesical Administration of Gemcitabine in Superficial Bladder Cancer: A Phase I Study with Pharmacodynamic Evaluation. A Phase II Study with Chemoresection of the Marker Lesion

Article • The Journal of Urology, April 2004, Wolters Kluwer Health

Professor Godefridus J Peters
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer

Article • Annals of Oncology, March 2004, Elsevier

Professor Godefridus J Peters
Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation

Article • BJU International, February 2004, Wiley

Professor Godefridus J Peters
Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods

Article • Molecular Imaging and Biology, October 2003, Elsevier

Adriaan Lammertsma, Professor Godefridus J Peters
An Expedient Assay for Determination of Gemcitabine and Its Metabolite in Human Plasma Using Isocratic Ion-Pair Reversed-Phase High-Performance Liquid Chromatography

Article • Therapeutic Drug Monitoring, October 2003, Wolters Kluwer Health

Professor Godefridus J Peters
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma

Article • British Journal of Cancer, August 2003, Springer Science + Business Media

Professor Godefridus J Peters
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

Article • British Journal of Cancer, June 2003, Springer Science + Business Media

Professor Godefridus J Peters
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors

Article • Cancer Chemotherapy and Pharmacology, May 2003, Springer Science + Business Media

Professor Godefridus J Peters
Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity

Article • British Journal of Cancer, March 2003, Springer Science + Business Media

Professor Godefridus J Peters
The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis

Article • Biochemical Pharmacology, March 2003, Elsevier

Professor Godefridus J Peters
Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia Cells

Article • Journal of Biological Chemistry, February 2003, Elsevier

Professor Godefridus J Peters
Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines

Article • International Journal of Oncology, January 2003, Spandidos Publications

Professor Godefridus J Peters
Thymidylate synthase inhibitors

Article • January 2003, Elsevier

Professor Godefridus J Peters
Effects of antifolates on the binding of 5-fluoro-2′-deoxyuridine monophosphate to thymidylate synthase

Article • Biochemical Pharmacology, August 2002, Elsevier

Professor Godefridus J Peters
3′-Azido-2′,3′-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells

Article • Biochemical Pharmacology, July 2002, Elsevier

Professor Godefridus J Peters
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, July 2002, Elsevier

Professor Godefridus J Peters
Gemcitabine–radiotherapy in patients with locally advanced pancreatic cancer

Article • European Journal of Cancer, June 2002, Elsevier

Professor Godefridus J Peters
Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Article • Journal of Clinical Oncology, March 2002, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside

Article • Cell Death and Differentiation, February 2002, Springer Science + Business Media

Professor Godefridus J Peters
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome

Article • Blood, January 2002, American Society of Hematology

Professor Godefridus J Peters
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin

Article • European Journal of Cancer, January 2002, Elsevier

Professor Godefridus J Peters
Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using standardized RT (StaRT)-PCR

Article • Molecular Diagnosis, December 2001, Elsevier

Professor Godefridus J Peters
Fluorouracil (5FU) Pharmacokinetics in 5FU Prodrug Formulations With a Dihydropyrimidine Dehydrogenase Inhibitor

Article • Journal of Clinical Oncology, November 2001, American Society of Clinical Oncology (ASCO)

Professor Godefridus J Peters
Folate homeostasis and antiproliferative activity of folates and antifolates

Article • Nutrition, September 2001, Elsevier

Professor Godefridus J Peters
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer

Article • Brazilian Journal of Medical and Biological Research, September 2001, FapUNIFESP (SciELO)

Professor Godefridus J Peters
Chemotherapeutic Strategies for Treatment of Colorectal Cancer: Present and Future Developments

Article • Clinical Colorectal Cancer, August 2001, Elsevier

Professor Godefridus J Peters
Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay

Article • International Journal of Oncology, July 2001, Spandidos Publications

Professor Godefridus J Peters
Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines11Abbreviations: ara-C,1-β-d-arabinofuranosylcytosine; dCDA, deoxycytid...

Article • Biochemical Pharmacology, June 2001, Elsevier

Professor Godefridus J Peters
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer

Article • Annals of Oncology, June 2001, Elsevier

Professor Godefridus J Peters
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox

Article • Experimental Hematology, May 2001, Elsevier

Professor Godefridus J Peters
A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia

Article • European Journal of Cancer, March 2001, Elsevier

Professor Godefridus J Peters
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients

Article • Annals of Oncology, February 2001, Elsevier

Professor Godefridus J Peters
Issues of Normal Tissue Toxicity in Patient and Animal Studies - Effect of Carbogen Breathing in Rats after 5-Fluorouracil Treatment

Article • Acta Oncologica, January 2001, Acta Dermato-Venereologica

Professor Godefridus J Peters
Biological Activity of 1-Deazapurine Nucleosides: Role of Deoxycytidine Kinase?

Article • Nucleosides and Nucleotides, April 1999, Taylor & Francis

Professor Godefridus J Peters
IN-VITRO SCHEDULE-DEPENDENCY OF EO9 AND MILTEFOSINE IN COMPARISON TO STANDARD DRUGS IN COLON-CANCER CELLS

Article • International Journal of Oncology, March 1994, Spandidos Publications

Professor Godefridus J Peters

Search

Main menu

Discover

Subjects on Kudos

Services and resources

Admin

All Stories